Pancreatic Cancer Research

ResearcherUniversity of TsukubaActive in the last 2 years

Tsuyoshi Enomoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0540-2239; OpenAlex author ID A5046290767. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 9

  1. Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-02404-1↗
  2. Total Superior Mesenteric Artery Nerve Plexus Preservation During Pancreaticoduodenectomy for Pancreatic Cancer. Last author DOI 10.1007/s00268-023-07111-4↗
  3. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic duc… Co-author DOI 10.1016/j.suronc.2021.101542↗
  4. Novel Pancreatic Cancer Therapy Targeting Cell Surface Glycans by Liposomes Modified with rBC2LCN Lectin. Co-author DOI 10.1159/000513430↗
  5. Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000697↗
  6. Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer. Co-author DOI 10.1111/cas.12888↗
  7. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. Co-author DOI 10.1038/bjc.2014.49↗
  8. Histological advantages of the tumor graft: a murine model involving transplantation of human pancreatic cancer tissue fragments. Co-author DOI 10.1097/mpa.0b013e318296f866↗
  9. Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer. Co-author DOI 10.1111/cas.12198↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tatsuya Oda · 9 shared papers, 2013–2025 · strength 0.85
  2. Osamu Shimomura · 5 shared papers, 2016–2025 · strength 0.68
  3. Yoshihiro Miyazaki · 4 shared papers, 2020–2025 · strength 0.63
  4. Yusuke Ohara · 7 shared papers, 2013–2023 · strength 0.50
  5. Yoshimasa Akashi · 7 shared papers, 2013–2023 · strength 0.50
  6. Hiroaki Tateno · 2 shared papers, 2020–2025 · strength 0.35
  7. Shuntaro Tsukamoto · 1 shared paper, 2025 · strength 0.25
  8. Hiromitsu Nakahashi · 1 shared paper, 2025 · strength 0.25
  9. Ryoichi Miyamoto · 5 shared papers, 2013–2017 · strength 0.23
  10. Nobuhiro Ohkohchi · 4 shared papers, 2013–2017 · strength 0.19
  11. Tomohiro Kurokawa · 3 shared papers, 2014–2017 · strength 0.16
  12. Hideyuki Sakurai · 1 shared paper, 2021 · strength 0.11
  13. Yuichi Hiroshima · 1 shared paper, 2021 · strength 0.11
  14. Haruko Numajiri · 1 shared paper, 2021 · strength 0.11
  15. Sota Kimura · 1 shared paper, 2020 · strength 0.11
  16. Tomoaki Furuta · 1 shared paper, 2020 · strength 0.11
  17. Yukihito Kuroda · 1 shared paper, 2020 · strength 0.11
  18. Nobuhiro Ohkochi · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.